RTP Mobile Logo
Select Publications

Abida W et al. Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair-deficient metastatic castration-resistant prostate cancer: Updated analyses. ESMO Congress 2019;Abstract 846PD.

André F et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380(20):1929-40. Abstract

Bastos DA, Antonarakis ES. Darolutamide for castration-resistant prostate cancer. Onco Targets Ther 2019;12:8769-77. Abstract

Chowdhury S et al. Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). ESMO Congress 2018;Abstract 795PD.

Corcoran RB et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2(3):227-35. Abstract

Dawson SJ et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013;368(13):1199-209. Abstract

De Roock W et al. KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12(6):594-603. Abstract

Dustin D et al. ESR1 mutations in breast cancer. Cancer 2019;125(21):3714-28. Abstract

Fribbens C et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016;34(25):2961-8. Abstract

Gong J et al. Value-based genomics. Oncotarget 2018;9(21):15792-815. Abstract

Goodall J et al. Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition. Cancer Discov 2017;7(9):1006-17. Abstract

Gray SW et al. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol 2014;32(13):1317-23. Abstract

Huijberts S et al. BEACON CRC (binimetinib [BINI], encorafenib [ENCO], and cetuximab [CTX] combined to treat BRAF-mutant metastatic colorectal cancer [mCRC]): A multicenter, randomized, open-label, three-arm phase III study of ENCO plus CTX plus or minus BINI vs irinotecan (IRI)/CTX or infusional 5-fluorouracil/folinic acid/IRI (FOLFIRI)/CTX with a safety lead-in of ENCO + BINI + CTX in patients (Pts) with BRAFV600E mCRC. ASCO 2017;Abstract TPS3622.

Hussain M et al. PROfound: Phase 3 study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations. ESMO Congress 2019;Abstract LBA12_PR.

Jamal-Hanjani M et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017;376(22):2109-21. Abstract

Kim TM et al. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 2013;155(4):858-68. Abstract

Kopetz S et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019;381(17):1632-43. Abstract

Kopetz S et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). ASCO 2017;Abstract 3505.

Le DT et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol 2019;[Epub ahead of print]. Abstract

Le DT et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372(26):2509-20. Abstract

Mao M et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013;19(3):657-67. Abstract

Mateo J et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. Abstract

Melo SA et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 2014;26(5):707-21. Abstract

Overman MJ et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol 2018;36(8):773-9. Abstract

Popovici V et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J Clin Oncol 2012;30(12):1288-95. Abstract

Prahallad A et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483(7387):100-3. Abstract

Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28. Abstract

Robson ME et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30(4):558-66. Abstract

Robson M et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377(6):523-33. Abstract

Sartore-Bianchi A et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17(6):738-46. Abstract

Schmid P et al. IMpassion130: Updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). ASCO 2019;Abstract 1003.

Schmid P et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108-21. Abstract

Sepulveda AR et al. Molecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35(13):1453-86. Abstract

Shenderov E et al. Genomic and clinical characterization of pulmonary-only metastatic prostate cancer: A unique molecular subtype. Prostate 2019;79(13):1572-9. Abstract

Smith MR et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer and biallelic DNA-repair gene defects: Preliminary results of GALAHAD. ESMO Congress 2019;Abstract LBA50.

Tsimberidou AM et al. Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 2012;18(22):6373-83. Abstract

Willis J et al. Validation of microsatellite instability detection using a comprehensive plasma-based genotyping panel. Clin Cancer Res 2019;25(23):7035-45. Abstract